[HTML][HTML] Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
W Holman, W Holman, S McIntosh, W Painter… - Trials, 2021 - Springer
A recently published article described the safety, tolerability, and pharmacokinetic profile of
molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe …
molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe …
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
AK Singh, A Singh, R Singh, A Misra - Diabetes & Metabolic Syndrome …, 2022 - Elsevier
Background and aims Molnupiravir is a newer oral antiviral drug that has recently received
emergency use authorization (EUA) in USA, UK and India. We aim to conduct an update on …
emergency use authorization (EUA) in USA, UK and India. We aim to conduct an update on …
[HTML][HTML] Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo …
SH Khoo, R FitzGerald, G Saunders… - The Lancet Infectious …, 2023 - thelancet.com
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
[HTML][HTML] Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
R Flisiak, D Zarębska-Michaluk, M Rogalska… - Pharmacological …, 2022 - Springer
Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …
[HTML][HTML] Molnupiravir: A versatile prodrug against SARS-CoV-2 variants
The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …
[HTML][HTML] The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era
The quest for effective drugs to treat COVID-19 has been a priority since the outbreak of the
disease. The clinical application of remdesivir has been greatly restricted by the need for …
disease. The clinical application of remdesivir has been greatly restricted by the need for …
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19： a meta-analysis
W Wen, C Chen, J Tang, C Wang, M Zhou… - Annals of …, 2022 - Taylor & Francis
Background The coronavirus disease (COVID-19) epidemic has not been completely
controlled. Although great achievements have been made in COVID-19 research and many …
controlled. Although great achievements have been made in COVID-19 research and many …
[HTML][HTML] Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2 …
WHK Schilling, P Jittamala, JA Watson… - The Lancet Infectious …, 2024 - thelancet.com
Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …
19 antiviral treatments, but their antiviral activities in patients have not been compared …
[HTML][HTML] The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
R Abdelnabi, CS Foo, SJF Kaptein, X Zhang… - …, 2021 - thelancet.com
Abstract Background Favipiravir and Molnupiravir, orally available antivirals, have been
reported to exert antiviral activity against SARS-CoV-2. First efficacy data have been recently …
reported to exert antiviral activity against SARS-CoV-2. First efficacy data have been recently …
[HTML][HTML] RdRp inhibitors and COVID-19: Is molnupiravir a good option?
SMR Hashemian, MH Pourhanifeh, MR Hamblin… - Biomedicine & …, 2022 - Elsevier
Rapid changes in the viral genome allow viruses to evade threats posed by the host immune
response or antiviral drugs, and can lead to viral persistence in the host cells. RNA …
response or antiviral drugs, and can lead to viral persistence in the host cells. RNA …